untitled

Size: px
Start display at page:

Download "untitled"

Transcription

1 PS3 10% 2-1

2 2-2

3 2-3

4

5

6

7 5 5% : (CVC) 5 2-7

8 CTZ

9 HT

10 FU 2-10

11 FU 2-11

12 2-12

13 (CTZ) 5HT3 H1 Achm (CTZ) D2 5HT3 NK1 H1 Achm 5HT2,, Achm D2 5HT3 Oxford Textbook of Palliative Medicine 3rd

14 ( 24 5HT3 5HT3 ASCO HT3 2-14

15 ASCO < ASCO 2-15

16 ASCO seavomiting.html 2-16

17 1496 BRM //

18 CHOP

19 2-19

20 L ml 9L) 2L 1L 2L 2L 1L 1L 9L) 35L 24L 12L mL O FUTS-1UFT 5-FU

21 10 2 SN

22 (PS) /mm 3 100/mm 3 38 G-CSF 2-22

23 ,000/mm

24

25

26 3540% QOL

27 5-FU 5-FU E

28 2-28

29

30 FU 2-30

31 QOL (FGFR) PLWC(people living with cancer) erlotinib ( Tarceva) cetuximab ( Erbitux) EGFR ee37a01d/?vgnextoid=81dd2daf1034b010vgnvcm100000ed730ad1rcrd EGFR EGFR

32 SPF 30 1/

33 15 24 T erlotinib ( Tarceva) cetuximab ( Erbitux) URL 2-33

34 QOL QOL 2-34

35 2-35

36 5-FUUFTTS-1 5-FU 5-FUUFTTS

37 2-37

38 95 5% /mm /mm /mm /mm /mm 3 95 CEA CEA

39 2-39

40 QOL QOL QOL QOL QOL QOL QOL QOL QOL 30 EORTC 30 (C30) QOL QLQ EORTC-QLQ-C30 FACT-G 2 1 QOL QOL QOL QOL

41 QOL QOL QOL QOL QOL QOL QOL QOL QOL EORTC-QLQ-C30 EORTC-QLC-C30 QOL QOL QOL QOL QOL 2-41

Microsoft Word - ランチョンプレゼンテーション詳細.doc

Microsoft Word - ランチョンプレゼンテーション詳細.doc PS1-1-1 PS1-1-2 PS1-1-3 PS1-1-4 PS1-1-5 PS1-1-6 PS1-1-7 PS1-1-8 PS1-1-9 1 25 12:4514:18 25 12:4513:15 B PS1-1-10 PS1-2-1 PS1-2-2 PS1-2-3 PS1-2-4 PS1-2-5 PS1-2-6 25 13:1513:36 B PS1-2-7 PS1-3-1 PS1-3-2

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information

untitled

untitled NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

More information

1 911 34/ 22 1012 2/ 20 69 3/ 22 69 1/ 22 69 3/ 22 69 1/ 22 68 3/ 22 68 1/ 3 8 D 0.0900.129mm 0.1300.179mm 0.1800.199mm 0.1000.139mm 0.1400.409mm 0.4101.199mm 0.0900.139mm 0.1400.269mm 0.2700.289mm

More information

1 2 http://www.japan-shop.jp/ 3 4 http://www.japan-shop.jp/ 5 6 http://www.japan-shop.jp/ 7 2,930mm 2,700 mm 2,950mm 2,930mm 2,950mm 2,700mm 2,930mm 2,950mm 2,700mm 8 http://www.japan-shop.jp/ 9 10 http://www.japan-shop.jp/

More information

第18回海岸シンポジウム報告書

第18回海岸シンポジウム報告書 2011.6.25 2011.6.26 L1 2011.6.27 L2 2011.7.6 2011.12.7 2011.10-12 2011.9-10 2012.3.9 23 2012.4, 2013.8.30 2012.6.13 2013.9 2011.7-2011.12-2012.4 2011.12.27 2013.9 1m30 1 2 3 4 5 6 m 5.0m 2.0m -5.0m 1.0m

More information

1 1 36 223 42 14 92 4 3 2 1 4 3 4 3429 13536 5 6 7 8 9 2.4m/ (M) (M) (M) (M) (M) 6.67.3 6.57.2 6.97.6 7.27.8 8.4 5 6 5 6 5 5 74 1,239 0 30 21 ( ) 1,639 3,898 0 1,084 887 2 5 0 2 2 4 22 1 3 1 ( :) 426 1500

More information

1 C 2 C 3 C 4 C 1 C 2 C 3 C

1 C 2 C 3 C 4 C 1 C 2 C 3 C 1 e N >. C 40 41 2 >. C 3 >.. C 26 >.. C .mm 4 C 106 e A 107 1 C 2 C 3 C 4 C 1 C 2 C 3 C 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124

More information

平成24年財政投融資計画PDF出後8/016‐030

平成24年財政投融資計画PDF出後8/016‐030 24 23 28,707,866 2,317,737 26,390,129 29,289,794 2,899,665 24 23 19,084,525 21,036,598 1952,073 24 23 8,603,613 8,393,427 967,631 925,404 202,440 179,834 217,469 219,963 66,716 64,877 3,160,423 2,951,165

More information

[mm] [mm] [mm] 70 60 50 40 30 20 10 1H 0 18 19 20 21 22 23 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1 2 3 4 5 6 7 8 9 10 11 12 60 50 40 30 20 10 0 18 19 20 21 22 23 24 1 2 3 4

More information

液晶ディスプレイ取説TD-E432/TD-E502/TD-E552/TD-E652/TD-E432D/TD-E502D

液晶ディスプレイ取説TD-E432/TD-E502/TD-E552/TD-E652/TD-E432D/TD-E502D 1 2 3 4 5 6 7 1 2 3 4 5 6 7 2 2 2 1 1 2 9 10 11 12 13 14 15 16 17 1 8 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10 9 11 12 13 13 14 15 16 17 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 11 12

More information

000-.\..

000-.\.. 1 1 1 2 3 4 5 6 7 8 9 e e 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 10mm 150mm 60mm 25mm 40mm 30mm 25 26 27 1 28 29 30 31 32 e e e e e e 33 e 34 35 35 e e e e 36 37 38 38 e e 39 e 1 40 e 41 e 42 43

More information

(1519) () 1 ( ) () 1 ( ) - 1 - - 2 - (1531) (25) 5 25,000 (25) 5 30,000 25,000 174 3 323 174 3 323 (1532) () 2 () 2-3 - - 4 - (1533) () 1 (2267)204 () (1)(2) () 1 (2267)204 () (1)(2) (3) (3) 840,000 680,000

More information

untitled

untitled 0120-888-089 0120-919-498 160-83381-26-1TEL. 03-3349-3111 URL http://www.sjnk.co.jp/ 160-83381-26-1 TEL. 03-3349-3111 URL http://www.sompo-japan.co.jp/ 100-89653-7-3 TEL. 0120-919-498 URL http://www.nipponkoa.co.jp/

More information

表紙.PDF

表紙.PDF 2 3 4 2001 2010 33 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 H18 21 22 23 24 25 26 27 28 29 30 31 32 33 300 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 410-8601 055-934-4747 Fax 055-933-1412

More information

農林金融2015年5月号

農林金融2015年5月号 4 5 4 4 4 4 2014 5 14 7 2050 1412 15 3 19 1800 1 1 2 2 2 126 2 3 1 2 1 2 3 4 1 1 2 2 1 1 2014 3 2 126 2 2 3 1 40 30 20 10 0 2014 26 287 339 393 399 361 2 2 11 1 3 25 4 4 5 5 19898993 96 3 2000 1 1 1 5

More information

No ( FAX ) (

No ( FAX ) ( 13-1 03-3862-9111 ( FAX03-3862- ) 9140 13-2 03-3219-8080 13-3 03-3293-1711 250 13-4 03-3292-2051 1-8 8111 13-5 8 11 28 ( 8 111 03-3261-5511 2 18 41 9 91 15 41 15 41 47 13-6 47 9 4 4 03-5343-5611 F 47 47

More information

2

2 1 2 119 119 5 500 1 30 102 1 113 3 4 120 2 3 113 5 230 1 1 3 4 5 6 7 8 1 support@kansen.sakura.ne.jp 2 9 3 ( ) 10 11 12 4 1. 2. 3. 4. 13 5 14 15 16 17 18 19 [ ] [ ] 20 [ ] [ ] [ ] 21 22 [ ] 23 < > < >

More information

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性 2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4

More information

indd

indd Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf

More information

chapter11.PDF

chapter11.PDF 11. 11.1. 11.1.1. 98 7 15 12 20 158 7/15 12/20 99 11 10 2000 3 31 11/10 3/31 2000 1 141 + 1 = 142 142 2000 3 27 99 12 10 451 344 = 107 2000 1 107 + 1 = 108 108 2000 6 27 98 12 20 98/12/20 99/12/20 2000/6/27

More information

障害者職域拡大カリキュラム研究会中間報告書構成案

障害者職域拡大カリキュラム研究会中間報告書構成案 3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16

More information

スライド 1

スライド 1 QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014

More information

無印良品 2012 自転車 カタログ

無印良品 2012 自転車 カタログ 26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417

More information

橡NO005-PDF用.ec5

橡NO005-PDF用.ec5 (Biotechnology, Cell Biology, Genetics, Immunology, Medicine, Neuroscience, Structural Biology) (Cancer, Genetics, Immunology, Molecular Cell Biology, Neuroscience) InfoPort TEL: 043-290-2262 FAX:

More information

23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213

More information

untitled

untitled . 23 3 2 1 2 3 21 21 22 9 1 23 18 4 5 6 5 40 20 7 1 1 8 9 10 11 12 50cm 13 10 11 14 2011 3 11 15 16 ml mm tel 079-557-0039 & fax 079-557-1888 17 248-240- 98-48- 170-98- 98- ml 85-1,085-18 19 20 21 22 23

More information

10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11

More information

2 / 7

2 / 7 1 / 7 1.30 1.301.00m 2.00 2.001.00m 1.70 1.701.00m 2.4 2.41.0m 2.0 2.01.0m 1.08 1.20.9m 1.08 1.20.9m 2.5 2.51.0m 2.5 2.51.0m 0.9 1.00.9m 1.44 1.60.9m 2 / 7 ml ml 3 / 7 4 / 7 ) 5 / 7 6 / 7 0798-56-1710

More information

0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2

0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216

More information

 

  10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2

More information

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2 (1) (2) SCI 2 SCI 2 24 2 12 2 2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

More information

GABA GABA

GABA GABA ( ) ITB QA ITB ITB intrathecal baclofen therapy GABA GABA 27mm 70mm g 18mL 9cm 5cm 2 1 24 2.5kg 2 13 1 416 57 25 6 20 6 19 1 2 MRl 1 2 QA 18 4 1 1 2 1 2 1 http //www.shakyo.or.jp / pamphlet.html QOL

More information

() 2

() 2 1 () 2 2 4 3 6,500 4 5 2 6 A B A B A B A B - A B 7 8 A B A B A B 9 JR JR 10 11 6 5 12 17 6 13 14 B A A B A B A B 2 1 8 15 8 16 17 9 18 3 4 5 mm mm 19 2 20 3 6 7 11 12 13 14 18 4 3 2 1 21 3 12 13 14 16

More information

4.11 4 55 4.12 11 56 4.13 0 57 4.14 1 58 4.15 4 59 4.16 11 60 5 5.1 5.1 5.2 1 (1983) Q = K A I v = Q / A = K I v = v / o n o Q A L 3 T -1 I : K : LT -1 v LT -1 v LT -1 o n o 61 (3) 5.3 1 5.1 K=10-1 10-3

More information

DocuPrint C5450 ユーザーズガイド

DocuPrint C5450 ユーザーズガイド 1 2 3 4 5 6 7 8 1 10 1 11 1 12 1 13 1 14 1 15 1 16 17 1 1 18 1 19 1 20 1 21 1 22 1 23 1 24 1 25 1 26 27 1 1 28 1 29 1 30 1 31 1 2 12 13 3 2 10 11 4 9 8 7 6 5 34 24 23 14 15 22 21 20 16 19 18 17 2 35

More information

-51-

-51- -50- -51- 11 3 28 8 1 24 7 2 36 10 1-52- -53- 1 2-54- 6 1 2 3 4 5 6 6 1 19 5 200 300ml 20 6 400ml -55- -56- 10-57- 4 2 20-58- 2,500-59- -60- -61- 2-62- 6 3-63- 9 68 1 6-64- 3-65- 4-66- 5 6-67- -68- 1 1

More information

2006年3月8日

2006年3月8日 18 21 1990 2004 2 2005 14 15 2004 1990 2005 2003 300 7 2 1 2005 1972 100 40 6 1972 2004 197 6,500 2004 21 59 100 65 2007 5 2005 30 1.8 535.89 348.33 187.56 2006 2006 5 1 30 1 30 46 46 1 46 1000kl 4 1 100kl

More information

90 27 1 29 ( ) 27 4 26 ( ) 27 4 29 ( ) 4 27 3 30 ( ) 1 30 4 27 4 8 ( ) 16 ( ) 9 P2 3 301 27 4 14 ( ) 15 ( ) 9 5 27 4 21 ( ) 4 27 4 21 ( ) 8 30 5 27 4 23 ( ) 5 10 11 12 13 4 3 4 14 27 4 23 ( 27 4 25 ( )

More information

2

2 1 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234

More information

a a b a b c d e R c d e A a b e a b a b c d a b c d e f a M a b f d a M b a b a M b a M b M M M R M a M b M c a M a R b A a b b a CF a b c a b a M b a b M a M b c a A b a b M b a A b a M b C a M C a M

More information